Semantic and Syntactic Computerized Analysis of Free Speech (ASESID)

Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic transition to validate a french predictive model of this transition using computerized speech analysis techniques

Study Overview

• Status: Recruiting
• Conditions: Psychotic Disorders; Psychosis; Schizophrenia and Related Disorders; Diagnosis, Psychiatric; Schizophrenia Prodromal

Detailed Description

Different scales allow identification of patients at ultra-high-risk to develop psychosis. The current challenge is to identify a predictive marker of transition to schizophrenia. Language disorders, which reflect psyche, could be one of these markers. Computerized speech analysis techniques such as Latent Semantic Analysis (LSA) have already proven their reliability in schizophrenia. These techniques reveal subtle speech disorganization that would be predictive of a clinical transition of ultra-high-risk psychotic patients. A combination of semantic and syntactic analysis could accurately predict the psychotic transition. The aim of our longitudinal multicenter cohort study is to validate this predicitve model in french language as well as identifying specific linguistic markers of the psychotic transition.

The initial report including the CAARMS is completed with an audio recording from the initial medical interview. The recording will be transcribed and analyzed by computer following the method of lemmatization and vectorial analysis (LSA). An analysis of the grammatical function (number of words, rate of the various grammatical functions) will also be performed. This first analysis will emerge linguistic markers correlated to transition to psychosis that we will use to construct a predictive model for transition to schizophrenia.

• Study Type: Observational
• Enrollment (Estimated): 150

Contacts and Locations

• Study Contact: Name: Michel WALTER; Phone Number: 02-98-01-51-57; Email: michel.walter@chu-brest.fr
• Study Contact Backup: Name: Christophe LEMEY; Email: christophe.lemey@chu-brest.fr

Study Locations

• France
  • Brest, France, 29609
    • Recruiting
    • CHRU de Brest
    • Contact: Michel WALTER; Email: michel.walter@chu-brest.fr
  • Caen, France
    • Not yet recruiting
    • Meunier Sophie
    • Contact: Sophie Meunier
  • Paris, France, 750144
    • Recruiting
    • CH de SAINT ANNE
    • Contact: Marie-Odile KREBS; Email: mo.krebs@ch-saint-anne.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 15 years to 30 years (Child, Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Help-seekers patients are recruited during two years from the early psychosis detection centers in Brest, France (CEVUP), Paris, France (CJAAD) and in Lausanne, Switzerland

Description

Inclusion Criteria:

• Major and/or minor from 15 to 30 years old
• Who alleged a suicidal gesture or idea or behavior that has repercussions in their emotional, social or professional life
• If patients receive neuroleptic treatment that impairs cognitive abilities, a one-week wash-out period will be scheduled prior to assessment.

Exclusion Criteria:

• History of psychosis
• Risk of self-harm or violence not compatible with outpatient treatment
• QI<70 (WAIS)
• Neurological disorder or major health problem
• Impossibility to interrupt neuroleptic treatment for one week
• Refusal to participate

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Transition to schizophrenia	Determined from the CAARMS scale (COMPREHENSIVE ASSESSMENT OF AT RISK MENTAL STATES)	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identification of patients at "ultra high risk " for developing schizophrenia	Determined from the CAARMS scale ( COMPREHENSIVE ASSESSMENT OF AT RISK MENTAL STATES)	Day 0

Collaborators and Investigators

• Sponsor: University Hospital, Brest

Study record dates

Study Major Dates

• Study Start (Actual): May 18, 2018
• Primary Completion (Estimated): June 30, 2024
• Study Completion (Estimated): June 30, 2024

Study Registration Dates

• First Submitted: April 26, 2018
• First Submitted That Met QC Criteria: May 14, 2018
• First Posted (Actual): May 15, 2018

Study Record Updates

• Last Update Posted (Actual): July 13, 2023
• Last Update Submitted That Met QC Criteria: July 12, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: Psychotic Disorders; Machine Learning; Ultra High Risk; Diagnosis, Psychiatric; Schizophrenia Prodromal; Prediction Of Psychosis; Automated Language Analysis; Semantic Coherence; Syntaxic Complexity
• Additional Relevant MeSH Terms: Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia; Psychotic Disorders; Mental Disorders
• Other Study ID Numbers: ASESID (29BRC17.0198)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No